FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379981569> ?p ?o ?g. }

• W4379981569 endingPage "536" @default.
• W4379981569 startingPage "534" @default.
• W4379981569 abstract "Introduction: Patients undergoing CAR T-cell therapy may experience severe cytopenias due to lymphodepleting chemotherapy and/or CAR T-cells. Transfusion needs represent a surrogate marker of severe anemia and thrombocytopenia. Transfusion needs may impact patients’ quality of life and CAR T-cells efficacy through transfusion-related immunomodulation. Here, we aimed to describe transfusion needs of patients receiving commercial CD19 CAR T-cells for relapse or refractory large B-cell lymphoma (LBCL), identify predictive factors associated with transfusions and search for correlations with CAR T-cells efficacy. Methods: Clinical data were collected form the DESCAR-T registry, the French national real-life registry for all patients treated with commercial CAR T-cells. Transfusion data were collected from the French national blood bank. We included all LBCL patients with at least 6-months follow-up from CAR T-cell infusion. Patients were censored for transfusions at relapse, new treatment onset, or death. Results: From August 2018 to September 2022, 671 patients in the DESCAR-T registry met the eligibility criteria. Overall, 382 patients (56.9%) received at least one transfusion after CAR T-cell infusion: 53.5% at the early phase (i.e. within the first month), and 37.8% at the late phase (i.e. beyond one month). Only 6% of the patients required transfusions beyond 3 months. The mean number of red blood cells (RBC) units and platelets transfusion per patient after CAR T-cell therapy were 3.5 (range, 0–90) and 5.1 (range, 0–127), respectively. Factors associated with transfusion needs after CAR T-cells therapy are presented in Table 1. Age, international prognostic index, primary refractory status, prior ASCT, bulk disease, and severe cytokine release syndrome (CRS) were associated with early but not late RBC transfusions. Early and late platelets transfusion shared the same risk factors except for severe CRS. No association was found between transfusions and response rate after CAR T-cell therapy. However, early transfusions (RBC and platelets) were associated with a shorter progression-free survival (median PFS = 3.2 vs. 6.0 months, p = 0.0168) and overall survival (median OS = 9.3 vs. 23.6 months, p < .0001). Late platelets transfusions were associated with decreased PFS (median = 5.6 vs. 12.0 months, p = 0.0072) and OS (median = 13.8 vs. NR, p < .0001) whereas late RBC transfusions did not impact PFS nor OS. Conclusion: In our study, 56.9% of patients received transfusions after CAR T-cell therapy. We identified risk factors associated with early and late transfusion needs. Early transfusions (RBC and platelets) and late platelets transfusion were associated with worse survival. Our data shed light on the mechanisms of early and late anemia and thrombocytopenia, and on the potential impact of transfusions on CAR T-cells efficacy. Encore Abstract - previously submitted to EHA 2023 Keywords: Aggressive B-cell non-Hodgkin lymphoma, Cellular therapies Conflicts of interests pertinent to the abstract. E. Bachy Honoraria: Kite, a Gilead Company, Bristol Myers Squibb, Novartis, Pfizer, Incyte, ADC Therapeutics Research funding: Amgen, BMS Other remuneration: Kite, a Gilead Company, Bristol Myers Squibb, Novartis, Pfizer G. Cartron Consultant or advisory role: Roche, Celgene-BMS, Onwards Therapeutics, MedxCell, EmerCell, MabQi Honoraria: Sanofi, Abbvie, Takeda, Roche, Janssen, Roche, Celgene, Novartis, Incyte Other remuneration: Consulting fees from from Roche and Celgene-BMS T. Gastinne Consultant or advisory role: Takeda, Gilead Sciences Honoraria: Pfizer, Takeda, Gilead Sciences Educational grants: Roche, Pfizer F. Morschhauser Consultant or advisory role: Novartis and Gilead K. Bouabdallah Consultant or advisory role: Kite/Gilead, Takeda Honoraria: Kite/Gilead, Takeda Educational grants: Kite/Gilead O. Casasnovas Consultant or advisory role: ROCHE, TAKEDA, GLIEAD/KITE, MSD, BMS Honoraria: ROCHE, TAKEDA, GILEAD/KITE, MSD, BMS, AMGEN, ABBVIE, JANSSEN Educational grants: ROCHE, TAKEDA, GILEAD/KITE, MSD, BMS, AMGEN, ABBVIE, JANSSEN Other remuneration: ROCHE, TAKEDA, GILEAD/KITE (research funding to the institution) S. Choquet Other remuneration: Novartis, Kite Gilead C. Castilla-Llorente Honoraria: Gilead/Kite S. Guidez Honoraria: Gilead, Novartis, Incyte, Roche M. Loschi Honoraria: Alexion, BMS Celgene, Gilead, Iqone, MSD, Novartis, Pfizer, Sanofi and Sobi L. Drieu La Rochelle Consultant or advisory role: Gilead/kite Educational grants: TAKEDA, Gilead/kite R. Houot Consultant or advisory role: Kite/Gilead, Novartis, Bristol-Myers Squibb/Celgene, ADC Therapeutics, Incyte, Miltenyi Honoraria: Kite/Gilead, Novartis, Incyte, Janssen, MSD, Takeda and Roche" @default.
• W4379981569 created "2023-06-10" @default.
• W4379981569 creator A5004965329 @default.
• W4379981569 creator A5005432295 @default.
• W4379981569 creator A5012400523 @default.
• W4379981569 creator A5014153145 @default.
• W4379981569 creator A5017140592 @default.
• W4379981569 creator A5020996390 @default.
• W4379981569 creator A5027624956 @default.
• W4379981569 creator A5031216970 @default.
• W4379981569 creator A5031977714 @default.
• W4379981569 creator A5043268917 @default.
• W4379981569 creator A5047928065 @default.
• W4379981569 creator A5051605599 @default.
• W4379981569 creator A5053019069 @default.
• W4379981569 creator A5053548417 @default.
• W4379981569 creator A5059752314 @default.
• W4379981569 creator A5065205435 @default.
• W4379981569 creator A5068452218 @default.
• W4379981569 creator A5069761611 @default.
• W4379981569 creator A5074554121 @default.
• W4379981569 creator A5078250435 @default.
• W4379981569 creator A5083573479 @default.
• W4379981569 date "2023-06-01" @default.
• W4379981569 modified "2023-10-12" @default.
• W4379981569 title "Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study." @default.
• W4379981569 doi "https://doi.org/10.1002/hon.3164_397" @default.
• W4379981569 hasPublicationYear "2023" @default.
• W4379981569 type Work @default.
• W4379981569 citedByCount "0" @default.
• W4379981569 crossrefType "journal-article" @default.
• W4379981569 hasAuthorship W4379981569A5004965329 @default.
• W4379981569 hasAuthorship W4379981569A5005432295 @default.
• W4379981569 hasAuthorship W4379981569A5012400523 @default.
• W4379981569 hasAuthorship W4379981569A5014153145 @default.
• W4379981569 hasAuthorship W4379981569A5017140592 @default.
• W4379981569 hasAuthorship W4379981569A5020996390 @default.
• W4379981569 hasAuthorship W4379981569A5027624956 @default.
• W4379981569 hasAuthorship W4379981569A5031216970 @default.
• W4379981569 hasAuthorship W4379981569A5031977714 @default.
• W4379981569 hasAuthorship W4379981569A5043268917 @default.
• W4379981569 hasAuthorship W4379981569A5047928065 @default.
• W4379981569 hasAuthorship W4379981569A5051605599 @default.
• W4379981569 hasAuthorship W4379981569A5053019069 @default.
• W4379981569 hasAuthorship W4379981569A5053548417 @default.
• W4379981569 hasAuthorship W4379981569A5059752314 @default.
• W4379981569 hasAuthorship W4379981569A5065205435 @default.
• W4379981569 hasAuthorship W4379981569A5068452218 @default.
• W4379981569 hasAuthorship W4379981569A5069761611 @default.
• W4379981569 hasAuthorship W4379981569A5074554121 @default.
• W4379981569 hasAuthorship W4379981569A5078250435 @default.
• W4379981569 hasAuthorship W4379981569A5083573479 @default.
• W4379981569 hasBestOaLocation W43799815691 @default.
• W4379981569 hasConcept C121332964 @default.
• W4379981569 hasConcept C126322002 @default.
• W4379981569 hasConcept C141071460 @default.
• W4379981569 hasConcept C142424586 @default.
• W4379981569 hasConcept C187212893 @default.
• W4379981569 hasConcept C203014093 @default.
• W4379981569 hasConcept C2776090121 @default.
• W4379981569 hasConcept C2778248108 @default.
• W4379981569 hasConcept C2778957590 @default.
• W4379981569 hasConcept C2779338263 @default.
• W4379981569 hasConcept C2780014101 @default.
• W4379981569 hasConcept C3017910909 @default.
• W4379981569 hasConcept C3875195 @default.
• W4379981569 hasConcept C71924100 @default.
• W4379981569 hasConcept C87355193 @default.
• W4379981569 hasConcept C8891405 @default.
• W4379981569 hasConceptScore W4379981569C121332964 @default.
• W4379981569 hasConceptScore W4379981569C126322002 @default.
• W4379981569 hasConceptScore W4379981569C141071460 @default.
• W4379981569 hasConceptScore W4379981569C142424586 @default.
• W4379981569 hasConceptScore W4379981569C187212893 @default.
• W4379981569 hasConceptScore W4379981569C203014093 @default.
• W4379981569 hasConceptScore W4379981569C2776090121 @default.
• W4379981569 hasConceptScore W4379981569C2778248108 @default.
• W4379981569 hasConceptScore W4379981569C2778957590 @default.
• W4379981569 hasConceptScore W4379981569C2779338263 @default.
• W4379981569 hasConceptScore W4379981569C2780014101 @default.
• W4379981569 hasConceptScore W4379981569C3017910909 @default.
• W4379981569 hasConceptScore W4379981569C3875195 @default.
• W4379981569 hasConceptScore W4379981569C71924100 @default.
• W4379981569 hasConceptScore W4379981569C87355193 @default.
• W4379981569 hasConceptScore W4379981569C8891405 @default.
• W4379981569 hasIssue "S2" @default.
• W4379981569 hasLocation W43799815691 @default.
• W4379981569 hasOpenAccess W4379981569 @default.
• W4379981569 hasPrimaryLocation W43799815691 @default.
• W4379981569 hasRelatedWork W1619537825 @default.
• W4379981569 hasRelatedWork W2580377636 @default.
• W4379981569 hasRelatedWork W2952578922 @default.
• W4379981569 hasRelatedWork W3004611567 @default.
• W4379981569 hasRelatedWork W3018061029 @default.
• W4379981569 hasRelatedWork W3177641494 @default.
• W4379981569 hasRelatedWork W3188370826 @default.
• W4379981569 hasRelatedWork W4249018146 @default.
• W4379981569 hasRelatedWork W4283270985 @default.

• next